LitCovid-sentences  

PMC:7536954 / 144-5218 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T3 0-12 Sentence denotes Dear Editor,
T4 13-315 Sentence denotes Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent.
T5 316-520 Sentence denotes Nevertheless, the presence of autoimmune conditions, particularly systemic lupus erythematosus (SLE), may represent a contraindication to the use of TNF‐α inhibitors due to the risk of drug‐induced lupus.
T6 521-693 Sentence denotes 1 Thus, the unique association of HS with SLE may require the off‐label use of immune‐targeted therapies that is cautiously monitored during the current COVID‐19 pandemic.
T7 694-844 Sentence denotes We report one patient with HS and SLE who developed COVID‐19 infection during treatment with off‐label secukinumab associated with hydroxychloroquine.
T8 845-980 Sentence denotes Since COVID‐19 infection was diagnosed, secukinumab was interrupted, and azithromycin was combined with hydroxychloroquine for 2 weeks.
T9 981-1159 Sentence denotes When COVID‐19‐related symptoms completely resolved, nasopharyngeal swab results were negative and secukinumab therapy was reintroduced after 8 weeks from the last administration.
T10 1160-1389 Sentence denotes A 28‐year‐old woman presented with SLE since the age of 13, with renal involvement (class III nephritis), myocarditis, and antiphospholipid antibody syndrome that was previously treated with hydroxychloroquine and salicylic acid.
T11 1390-1475 Sentence denotes Medical history also included autoimmune thyroiditis, fibromyalgia, and osteoporosis.
T12 1476-1540 Sentence denotes First manifestations of HS were reported at the age of 20 years.
T13 1541-1694 Sentence denotes Frequent flares (>2 episodes/months) occurred, and minimal clinical and ultrasonographic improvements were obtained with previous HS‐specific treatments.
T14 1695-1828 Sentence denotes At our observation (Fig. 1a), the patient reported a worsening of disease associated with a relevant disease burden (Hurley II; IHS4:
T15 1829-1865 Sentence denotes 12; pain‐Numeric Rating Scale [NRS]:
T16 1866-1881 Sentence denotes 7/10; itch‐NRS:
T17 1882-1898 Sentence denotes 3/10; HidraDisk:
T18 1899-1941 Sentence denotes 62; Dermatology Life Quality Index [DLQI]:
T19 1942-1946 Sentence denotes 15).
T20 1947-2123 Sentence denotes Concomitant SLE showed low‐disease activity with current maintenance therapy consisting of hydroxychloroquine (400 mg/day), oral steroids, acetylsalicylic acid, and pregabalin.
T21 2124-2329 Sentence denotes Because adalimumab was considered contraindicated, off‐label subcutaneous secukinumab injections at the dosage of 300 mg at weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing, were prescribed.
T22 2330-2382 Sentence denotes Figure 1 Clinical response to secukinumab therapy.
T23 2383-2532 Sentence denotes Manifestations at the left axilla consisted of inflammatory HS nodules and fistulas prior to secukinumab therapy (a) and after 20‐week treatment (b).
T24 2533-2633 Sentence denotes After 20 weeks of secukinumab therapy (Fig. 1b), improvement of disease severity was observed (IHS4:
T25 2634-2646 Sentence denotes 8, pain‐NRS:
T26 2647-2666 Sentence denotes 0/10, and itch‐NRS:
T27 2667-2683 Sentence denotes 3/10; HidraDisk:
T28 2684-2713 Sentence denotes 13; DLQI:5; HiSCR: positive).
T29 2714-2971 Sentence denotes After 24weeks of secukinumab therapy, the patient referred a flu‐like episode initially characterized by diarrhea and then followed by ageusia, anosmia, sinusitis, fever (body temperature >38 °C), asthenia, myalgia, and arthralgia, without cough or dyspnea.
T30 2972-3123 Sentence denotes Nasopharyngeal swab was performed, as per COVID‐19 surveillance guidelines, resulting positive for SARS‐CoV‐2 on polymerase chain reaction (PCR) assay.
T31 3124-3219 Sentence denotes Secukinumab was interrupted, and azithromycin was combined with hydroxychloroquine for 2 weeks.
T32 3220-3319 Sentence denotes COVID‐19‐related symptoms completely resolved after 3 weeks with no worsening of HS manifestations.
T33 3320-3453 Sentence denotes Two nasopharyngeal swabs with a 48‐hour interval were performed after complete resolution of COVID‐19 symptoms and resulted negative.
T34 3454-3540 Sentence denotes Thus, secukinumab therapy was reintroduced after 8 weeks from the last administration.
T35 3541-3709 Sentence denotes Management of moderate to severe HS is challenging as no single drug is universally effective, thus requiring a personalized, patient‐by‐patient approach in most cases.
T36 3710-3822 Sentence denotes We reported an uncommon association of HS and SLE treated with secukinumab therapy during the COVID‐19 pandemic.
T37 3823-3935 Sentence denotes Previous publications reported clinical improvements obtained by IL‐17A inhibition in treating either HS or SLE.
T38 3936-4147 Sentence denotes 2 , 3 Secukinumab was successfully tested in an open‐label trial at two different doses that showed the majority of HS patients achieving HiSCR, suggesting that secukinumab could be as effective as adalimumab.
T39 4148-4478 Sentence denotes 3 Successful treatment of refractory lupus nephritis with secukinumab in a patient complicated with psoriasis vulgaris was described, highlighting that clinical benefits were associated with reduction of activated T helper 17 cells in peripheral blood and reduced infiltration of IL‐17‐positive lymphocytes in renal interstitium.
T40 4479-4575 Sentence denotes 4 Thus, we considered secukinumab as a treatment option that resulted effective in treating HS.
T41 4576-4908 Sentence denotes Notwithstanding the overall effectiveness on HS and no detrimental effects on SLE, secukinumab was interrupted when SARS‐Cov‐2 was diagnosed in accordance with established psoriasis treatment guidelines and the latest recommendations issued by national and international scientific societies on the management of COVID‐19 infection.
T42 4909-5072 Sentence denotes Notably, our case developed SARS‐Cov‐2 infection during hydroxychloroquine therapy, which is under evaluation for the current management of the COVID‐19 infection.
T43 5073-5074 Sentence denotes 5